Adénocarcinome bronchique avec mutation de l’ EGFR et réarrangement ALK concomitants
- 1 May 2017
- journal article
- case report
- Published by Elsevier BV in Revue des Maladies Respiratoires
- Vol. 34 (5), 576-580
- https://doi.org/10.1016/j.rmr.2016.08.002
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitorAnnals of Oncology, 2014
- Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors PhosphorylationClinical Cancer Research, 2014
- EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practiceBritish Journal of Cancer, 2013
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung CancerClinical Cancer Research, 2013
- Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocationLung Cancer, 2012
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2010
- Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expressionMolecular Cancer, 2010
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007